The CD44 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, designed to disrupt CD44 gene function. This pooled knockout model provides a genetically heterogeneous loss-of-function system, avoiding clonal artifacts and reflecting population-level gene disruption effects. As a research tool, it enables investigation of CD44-dependent processes in ovarian cancer without introducing single-cell clonal bias, making it suitable for studying collective cellular behaviors.
The parental A2780 cell line is a well-characterized model of human ovarian epithelial cancer, originally established from an untreated patient. It retains key features of ovarian carcinoma, including epithelial morphology and drug sensitivity profiles, and is widely employed to study ovarian cancer biology, chemoresistance, and metastatic progression. The A2780 background is particularly valued for its reproducible growth characteristics and responsiveness to hormonal and growth factor stimuli, offering a defined context for CD44 pathway interrogation.
CD44 encodes a multifunctional transmembrane glycoprotein that serves as the principal receptor for hyaluronan (HA). Ligand engagement by HA, osteopontin, or growth factors such as EGF and TGF-?? triggers CD44-mediated activation of PI3K/AKT and MAPK/ERK signaling cascades. These pathways modulate downstream effectors including Rho GTPases, ??-catenin, Snail, and MMP-9, orchestrating cytoskeletal reorganization, transcriptional reprogramming, and extracellular matrix remodeling. CD44 also physically associates with ERM proteins, ankyrin, Src, and HER2, linking extracellular cues to intracellular signaling networks that drive epithelial-mesenchymal transition (EMT) and cell survival.
In the A2780 ovarian carcinoma context, CD44 contributes to aggressive traits such as enhanced migration, invasion, and resistance to chemotherapeutic agents. Loss of CD44 function in these polyclonal knockout cells can attenuate HA-induced signaling, potentially reducing EMT marker expression and impairing metastatic capacity. This model permits researchers to dissect the role of CD44 in ovarian cancer progression, particularly in how hyaluronan-rich tumor microenvironments promote malignant behavior. It also offers a platform to investigate CD44-mediated interactions with other oncogenic pathways that are co-opted during ovarian cancer evolution.
These CD44 knockout cells are ideally suited for a broad range of functional assays, including Western blotting and RT-qPCR to confirm gene disruption and downstream signaling changes, migration and invasion assays to assess metastatic potential, and hyaluronan adhesion assays to quantify CD44 receptor activity. Flow cytometry enables surface marker profiling, while RNA-seq and co-immunoprecipitation facilitate global transcriptomic and protein?Cprotein interaction analyses. Phospho-AKT and phospho-ERK detection provides direct readouts of pathway activation. Key applications encompass ovarian cancer metastasis and drug resistance research, EMT signaling studies, anti-metastatic drug screening, tumor microenvironment interaction analyses, and cancer stem cell investigations. For additional details on batch-specific performance and customization options, please contact Ascent Research.
